Balanced T-cell response key to asymptomatic COVID-19, study suggests
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
List view / Grid view
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
Researchers have shown that administering a urinary tract infection vaccine directly to the bladders of mice helped them to effectively fight bacteria.
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.
A peptide administered to ferrets protected them from SARS-CoV-2 viral transmission when housed with infected ferrets.
A new vaccine is effective at preventing opioid overdose from fentanyl and carfentanil in rodents, according to a new study.
A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.